RMX Acquires China Rights to Novel Antibiotic from LegoChem

RMX Biopharma of Shanghai in-licensed China rights to a next-gen oxazolidinone antibiotic from South Korea's LegoChem Biosciences. RMX will develop, manufacture and market LCB01-0371in China. According to LegoChem, LCB01-0371 has shown improved activity over gram-positive super-bacteria that include MRSA, VRE and MDR-TB. The antibiotic is in early clinical trials. Although details of the agreement were not disclosed, RMX will make upfront and milestone payments, plus royalties. More details.... Share this with colleagues: // //